Key result
Changes in plasma renin activity and aldosterone concentrations 6 months after treatment for primary aldosteronism were associated with greater reductions in eGFR.
Why the study?
Little is known regarding the mechanisms underlying estimated glomerular filtration rate (eGFR) reduction after treatment for primary aldosteronism.
Are changes in plasma renin activity and aldosterone concentrations associated with changes in kidney function after treatment for primary aldosteronism?
Cohort (n=1,184)
Yes
Are changes in plasma renin activity and aldosterone concentrations associated with changes in kidney function after treatment for primary aldosteronism?
Mean Difference: -2.76 (95% CI -4.29–-1.22)
Improvements in glomerular hyperfiltration after treatment for primary aldosteronism are associated with changes in plasma renin activity and aldosterone concentrations, suggesting decreased mineralocorticoid receptor activity in the kidneys rather than systemic blood pressure reductions is responsible.
May guide closer eGFR monitoring after primary aldosteronism treatment; leaves open causal links to renin-aldosterone dynamics.
Introduction Greater reduction in estimated glomerular filtration rate (eGFR) after specific treatment for primary aldosteronism (PA) reflects improvement in glomerular hyperfiltration associated with PA and leads to better patient outcomes. However, little is known regarding the mechanisms underlying eGFR reduction after treatment for PA. Methods We analyzed data from the nationwide PA registry in Japan. Patients were assigned to adrenalectomy (n = 438) and mineralocorticoid receptor (MR) antagonist (n = 746) groups. We assessed associations between changes in blood pressure (BP), plasma renin activity (PRA) and plasma aldosterone concentrations (PAC), and eGFR before and 6 months after treatment for both groups. Results In a multivariable linear regression, the adjusted β values (95% confidence interval [CI]) for change in eGFR after treatment were −2.76 (−4.29, −1.22) ml/min per 1.73 m 2 for PRA (per 3.2 ng/ml per hour), and 1.97 (1.08, 2.85) ml/min per 1.73 m 2 for PAC (per 236.1 pg/ml) in the adrenalectomy group; and −0.45 (−0.89, −0.01) ml/min per 1.73 m 2 for PRA and −0.72 (−1.62, 0.18) ml/min per 1.73 m 2 for PAC in the MR antagonist group. Change in mean arterial pressure after treatment was not significantly associated with change in eGFR in either group. Changes in PRA and PAC but not BP before and 6 months after treatment for PA were associated with greater reductions in eGFR. Conclusion Post-treatment improvements in glomerular hyperfiltration may be attributable to decreased MR activity in the kidneys, but not to reductions in systemic BP.
No takes yet. Share an insight, caveat, or question.
Kobayashi et al. (2020) conducted a cohort in Primary aldosteronism (n=1,184). Changes in plasma renin activity and plasma aldosterone concentrations was evaluated on Change in estimated glomerular filtration rate (eGFR) after treatment (β -2.76, 95% CI -4.29, -1.22). Changes in plasma renin activity and aldosterone concentrations 6 months after treatment for primary aldosteronism were associated with greater reductions in eGFR.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: